SavedAdd your journal

Journals / Turkish Medical Student Journal / 2020 / Cilt: 7 - Sayı: 1

CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE

Beiza CHATZİSALİ
Tolga GAŞ
Hilmi KILGIN
Kübra Duvan AYDEMİR
Dilşat ERÜMİT
Ruhan Deniz TOPUZ
Ahmet ULUGÖL
Pages
1–4
Publication Date
2020-02-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Keywords: AM-251, AM-630, antinociception, cannabinoid receptors, diclofenac

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: It has been long suspected that the cannabinoid system participates in the antinociceptive effects of nonsteroidal anti-inflammatory drugs.
📊
Key Findings & Data:Methods: In our study, male BALB/c mice, weighing 20-30 g, were used.
💡
Conclusion & Impact:Keywords: AM-251, AM-630, antinociception, cannabinoid receptors, diclofenac
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:AM-251 · AM-630 · antinociception

Abstract

Aims: It has been long suspected that the cannabinoid system participates in the antinociceptive effects of nonsteroidal anti-inflammatory drugs. We studied the possible effects of cannabinoid receptor antagonism on diclofenac-induced antinociception in the writhing test in mice. Methods: In our study, male BALB/c mice, weighing 20-30 g, were used. Writhing responses were produced by intraperitoneal injection of 0.6% acetic acid. Different doses of diclofenac (3, 10, 30 mg/kg, i.p.) were tested, then the influence of AM-251 (1 mg/kg, i.p.), a cannabinoid CB1 receptor antagonist and AM-630 (3 mg/kg, i.p.), a cannabinoid CB2 receptor antagonist on the antinociceptive effects of diclofenac was studied. Results: Diclofenac administration elicited a significant, dose-dependent antinociceptive response; however, neither the cannabinoid CB1 receptor antagonist AM-251 nor the cannabinoid CB2 receptor antagonist AM-630 had any influence on the antinociceptive effect of diclofenac. Conclusion: Iinhibition of cannabinoid receptors does not contribute to the antinociceptive action of systemic diclofenac. Further studies are needed to explain the antinociceptive mechanism of diclofenac. Keywords: AM-251, AM-630, antinociception, cannabinoid receptors, diclofenac

🔖

Cite This Article

CHATZİSALİ, B., GAŞ, T., KILGIN, H., AYDEMİR, K. D., ERÜMİT, D., TOPUZ, R. D., ULUGÖL, A. (2020). CANNABINOID RECEPTORS ARE NOT INVOLVED IN ANTINOCICEPTION INDUCED BY SYSTEMIC DICLOFENAC IN MICE. Turkish Medical Student Journal, Cilt: 7 - Sayı: 1, 1–4. https://ajindex.com/articles/809876

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Ulugol A. The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J 2014;31:115-20
  2. Schrot RJ, Hubbard JR. Cannabinoids: medical implications. Ann Med 2016;48:128-41
  3. Sastre-Garriga J, Vila C, Clissold S et al. THC and CBD oromucosal spray (Sativex (R)) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 2011;11:627-37
  4. Mallet C, Daulhac L, Bonnefont J et al. Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 2008;139:190-200
  5. Rogosch T, Sinning C, Podlewski A et al. Novel bioactive metabolites of dipyrone (metamizol). Bioorgan Med Chem 2012;20:101-7
  6. Crunfli F, Vilela FC, Giusti-Paiva A. Cannabinoid CB1 receptors mediate the effects of dipyrone. Clin Exp Pharmacol P 2015;42:246- 55
  7. Hamza M, Dionne RA. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol 2009;2:1-14
  8. Paunescu H, Coman OA, Coman L et al. Cannabinoid system and cyclooxygenases inhibitors. J Med Life 2011;4:11-20
  9. Fowler CJ. NSAIDs: endocannabinoid stimulating anti-inflammatory drugs?. Trends Pharmacol Sci 2012;33:468-73
  10. Elmas P, Ulugol A. Involvement of cannabinoid CB1 receptors in the antinociceptive effect of dipyrone. J Neural Transm 2013;120:1533-8
  11. Schlosburg JE, Radanova L, Di Marzo V et al. Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice. Behav Pharmacol 2012;23:722-6
  12. Topuz RD, Gunduz O, Karadag HC et al. Endocannabinoid and N-acylethanolamide levels in rat brain and spinal cord following systemic dipyrone and paracetamol administration. Can J Physiol Pharmacol 2019;8:1-7
  13. Saglam G, Gunduz O, Ulugol A. Blockade of cannabinoid CB1 and CB2 receptors does not prevent the antipruritic effect of systemic paracetamol. Acta Neurol Belg 2014;114:307-9
  14. Anikwue R, Huffman JW, Martin ZL et al. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. J Pharmacol Exp Ther 2002;303:340-6
  15. Naidu PS, Booker L, Cravatt BF et al. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 2009;329:48-56
  16. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-10
  17. Ulugol A, Ozyigit F, Yesilyurt O et al. The additive antinoc